Compare CRDL & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | DFLI |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 94.4M |
| IPO Year | N/A | N/A |
| Metric | CRDL | DFLI |
|---|---|---|
| Price | $0.99 | $4.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.00 | ★ $22.50 |
| AVG Volume (30 Days) | 642.4K | ★ 1.1M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $57,783,000.00 |
| Revenue This Year | N/A | $17.85 |
| Revenue Next Year | N/A | $30.29 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.24 |
| 52 Week Low | $0.77 | $1.50 |
| 52 Week High | $1.59 | $38.90 |
| Indicator | CRDL | DFLI |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 80.96 |
| Support Level | $0.88 | $0.41 |
| Resistance Level | $1.03 | $5.15 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | -0.00 | 0.38 |
| Stochastic Oscillator | 7.29 | 79.00 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.